Schedule 13G ownership disclosure

Amylyx Pharmaceuticals Inc

Security class unavailable · CUSIP: 03237H101

Event date: Unavailable

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
4,002,334
Percent of class
5.9000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001086364-24-005648
Form type
SC 13G
Filer
Amylyx Pharmaceuticals, Inc.
CIK
CIK 1658551
Filed
Jan 29, 2024
Reporting period
—
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub